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Abstract 
Background: In the risk-assessment of patients considered for non-cardiac surgery and with 
recent coronary stent implantation, coronary drug-eluting stent implantation procedure 
characteristics may be taken into account. We aimed to evaluate associations between 
coronary drug-eluting stent implantation procedure characteristics and the risk of 
myocardial infarction and all-cause death within 30 days after non-cardiac surgery.  
Design: Patients with coronary drug-eluting stents were identified using the Western 
Denmark Heart Registry. Surgical procedures performed after stent implantation were 
detected using the Danish National Patient Registry. We used registry based detection of 
myocardial infarction and all-cause death. 
Results: Of 22,590 patients treated with drug-eluting stents between 2005 and 2012, 4,046 
underwent non-cardiac surgery within 1 and 12 months after stent implantation. We found 
no significant association between the risk of myocardial infarction or all-cause death within 
30 days after surgery and number of arteries treated (1 (reference) versus more), number of 
lesions treated (1 (reference) versus more), segments treated (left main and proximal left 
anterior descending artery versus other (reference), total stent length (< 20mm (reference) 
versus ≥20mm), number of stents (1 (reference) versus >1), and largest balloon diameter 
(≥3mm (reference) versus <3mm). All-cause death, but not myocardial infarction, risk was 
lower among patients treated with first generation versus second generation stents (odds 
ratio 0.58).  
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Conclusions: We identified no significant associations between stent implantation 
procedure characteristics and risk of myocardial infarction or all-cause death among 
patients undergoing non-cardiac surgery. All-cause death was lower with first versus second 
generation drug eluting stents. 
 
Key words: drug-eluting stents, non-cardiac surgery, myocardial infarction, all-cause death 
 
Introduction 
After coronary stent implantation, 5–25% of patients require non-cardiac 
surgery within 5 years after stent implantation.1 Guidelines advocate postponing surgery 
until termination of dual antiplatelet therapy.1,2 When surgery cannot be postponed, it is 
recommended that a multidisciplinary team assess the individual risk associated with 
surgery and make a plan for the surgery, including perioperative management of 
antiplatelet therapy, taking the risk of ischemic and bleeding events into account.1,2 In the 
risk assessment, individual factors such as stent implantation procedure characteristics (e.g., 
stent type, stent length, number of stents and stented vascular segment) may be taken into 
account. However, data justifying that procedural characteristics influence outcomes in 
relations to subsequent non-cardiac surgery are scarce.3–5 We aimed to evaluate the 
association between stent implantation procedure characteristics and risk of myocardial 
infarction and all-cause death among patients undergoing non-cardiac surgery between 1 
and 12 months after coronary drug-eluting stent implantation.  
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Methods 
The study was an observational registry-based study. In Denmark, registry-
based studies do not require ethical approval. The study was approved by the Danish Data 
Protection Agency (2012-41-0164).  
We evaluated the association between variables related to the drug-eluting 
stent implantation procedure and the risk of myocardial infarction and all-cause death. 
Patients undergoing non-cardiac surgery between 1 and 12 months after drug-eluting stent 
implantation were included. 
We evaluated the risk in relation to surgery within the first year after coronary drug-eluting 
stent implantation since the standard recommendation for dual antiplatelet therapy after 
coronary drug-eluting stent implantation was one year during the study period. Surgery 
performed within in the first month after coronary drug-eluting stent implantation was 
excluded since surgery performed within this period is most often urgent surgery associated 
with a higher risk than surgery performed more than one month after coronary DES 
implantation.6 We assessed 30-day postoperative risk of myocardial infarction and all-cause-
death. 
All patients treated with drug-eluting stent implantation between May 2005 
and January 2012 as registered in the Western Denmark Heart Registry and with a non-
cardiac surgical procedure in the Danish National Patient Registry within 1 to 12 months 
after drug-eluting stent implantation were included in the analysis. The cohort of patients 
treated with drug-eluting stent implantation between May 2005 and January 2012 has been 
previously described.6 We used registry-based event detection.7 
 
A
cc
ep
te
d
 A
rt
ic
le
 
 
This article is protected by copyright. All rights reserved. 
We evaluated the following stent implantation procedure characteristics: 
number of arteries treated (1 (reference) versus >1), number of lesions treated (1 
(reference) versus >1), treated segments (left main and proximal left anterior descending 
artery versus other segments (reference)), total stent length (<20mm (reference) versus 
≥20mm), number of stents (1 (reference) versus >1), drug-eluting stent generation (first 
versus second (reference)), and largest balloon diameter (<3mm versus ≥3mm (reference)).  
We evaluated associations between these characteristics and the outcomes, 
myocardial infarction and all-cause death using odds ratios. Myocardial infarction was 
defined as a discharge diagnosis of myocardial infarction from and acute admission as 
registered in the Danish National Patient Registry. This definition has recently been 
validated using patient chart review.8 All-cause death data were retrieved from the Danish 
Central Person Register.9 
 The included non-cardiac surgical procedures have been published earlier.6 Cardiac surgery 
was not included. 
Baseline patient demographics and stent implantation procedure 
characteristics (including procedure dates) were retrieved from the Western Denmark Heart 
Registry.10 This registry collects patient and procedure characteristics on all coronary 
procedures performed in Western Denmark, which covers 3 million inhabitants (55% of the 
Danish population). 
Dates of surgery, surgical procedure codes, and myocardial infarction diagnoses were 
retrieved from the Danish National Patient Registry.11 This registry collects data on all 
hospital admissions and outpatient clinic visits in all of Denmark. The collected data include 
codes for procedures and examinations as well as admission types and discharge diagnoses. 
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The Danish Central Person Register contains vital status on all Danish citizens and is updated 
daily.9 The Civil Personal Register number assigned to all Danish citizens in this registry 
allows for individual-level record linkage across the used registries. 
We used logistic regression to estimate crude odds ratios and odds ratios 
adjusted for age (≤ or >70 years) and gender. Kaplan-Meier failure estimate graphs were 
constructed for the myocardial infarction and all-cause death. Data were summarised and 
analysed using Stata/IC 13.1 for Windows.  
In a supplemental analysis, we adjusted the crude odds ratios for acute coronary syndrome 
as indication for stent implantation, year of stent implantation, time from stent 
implantation to surgery, and for European Society of Cardiology/European Society of 
Anesthesiology non-cardiac surgery risk group. 
 
Results 
A total of 22,590 patients were treated with drug-eluting stents in the study 
period (Figure 1). Of these, 4,046 patients underwent a subsequent surgical procedure 
within 1 to 12 months after coronary stent implantation. The baseline patient demographics 
and drug-eluting stent implantation procedure characteristics of these 4,046 patients are 
given in Tables 1 and 2. The surgical procedures were performed within a wide range of 
surgical specialties6 and were categorized as European Society of Cardiology/European 
Society of Anesthesiology non-cardiac surgery low (n=2,945), intermediate (n=1,014) and 
high (n=87) risk groups. 
Among 4,046 patients with a surgical procedure within 1 to 12 months after 
coronary stent implantation, 18 patients (0.4%) suffered a myocardial infarction and 88 
patients (2.2%) died within 30 days after surgery (Figure 2). 
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The odd ratios for myocardial infarction and all-cause death after non-cardiac 
surgery according to stent implantation procedure characteristics are given in Table 3.  
Overall, the 95% confidence intervals were wide as a consequence of the low 
event rates. Only, the odds ratio for the association between stent generation and all-cause 
death had a 95% confidence interval that did not span one with first generation stents being 
associated with a lower risk of death.  
In the supplemental analysis, adjustment for acute coronary syndrome as 
indication for stent implantation, year of stent implantation, time from stent implantation 
to surgery, and for European Society of Cardiology/European Society of Anesthesiology non-
cardiac surgery risk group did not change the crude odds ratios markedly (please, see the 
Supplementary table 1 and 2). Combining the endpoints myocardial infarction and all-cause 
death did not change the results (please see Supplementary table 3). 
The time interval between stent implantation and surgery did not differ between 
patients treated with first and second generation stents. Supplementary table 4 and 5 show the 
number of non-cardiac surgical procedures and risk of myocardial infarction and death according to 
time between stent implantation and non-cardiac surgery in the intervals 31-60 days, 61-90 days, 
91-180 days, 181-270 days, 271-365 days stratified according to stent generation. 
 
Discussion 
The main findings of the study are that the rates of myocardial infarction 
(0.4%) and all-cause death (2.2%) within 30 days after surgery were low and that there were 
no statistically significant associations between stent implantation procedure characteristics 
and risk of these events. However, there was a general trend towards a higher post-
operative risk with coronary stent treatment for more extensive or severe disease. 
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The observed rates of myocardial infarction and all-cause death within 30 days 
after non-cardiac surgery within 1 to 12 months after coronary drug eluting stent 
implantation were low. In previous studies, rates of myocardial infarction and death after 
non-cardiac surgery among patients with prior coronary drug-eluting stent implantation 
vary.3–5,12–15 These studies are heterogeneous. Some include patients treated with BMS or 
DES and others only include patients treated with DES. The follow-up intervals after stent 
implantation also differed. Moreover, the time intervals between stent implantation and 
surgery, the types of non-cardiac surgery included, and the follow-up time after surgery 
have varied and may have impacted results. For myocardial infarction, differences in 
definition of myocardial infarction and practices for assessment of biochemical markers of 
myocardial injury after surgery may lead to differences in detection.  
Although we included all patients treated with coronary drug-eluting stent 
implantation within the study period, selection of patients for surgery by the treating 
clinicians may have contributed to the observed low event rates. I.e., patients assumed to 
have a low risk in relation to surgery would be more likely to have surgery performed, 
whereas patients assumed to have higher risk would be more likely to have surgery deferred 
or postponed. In the available studies,3–5,12–15 including the current study, data describing 
the numbers and characteristics of patients considered for surgery after stent implantation, 
but who had surgery deferred or postponed, are lacking. Thus, the processes for selection of 
patients for surgery were not described. Therefore, the observed low risks of post-operative 
events may not apply to all patients, in whom surgery is considered during the first year 
after coronary drug-eluting stent implantation. Particularly, patients in the European Society 
of Cardiology/European Society of Anesthesiology non-cardiac surgery high risk group were 
not well-represented in this study. 
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Only the association between first generation drug-eluting stents and lower 
all-cause death was statistically significant. Since first generation drug-eluting stents are not 
currently implanted, this result no longer has clear clinical impact. The result seems 
counterintuitive and conflicting with previous data.12 The result could be a chance finding. 
However, it may also represent temporal changes in practice regarding the performance of 
surgery within the first year after implantation. First generation stents were implanted 
earlier in the study period than second generation stents and a more critical selection of 
very low risk patients for surgery during this period, with focus on late stent thrombosis, 
may have contributed to this result.  
Regarding the remaining stent procedure characteristic, there may be a 
general trend towards a higher post-operative risk with coronary stent treatment for more 
extensive or severe disease. The observed odds ratios have wide 95% confidence intervals 
as a consequence of the observed low event rates. However, the best estimates in this study 
are that the risk of myocardial infarction is increased approximately 77% with stent 
treatment of the left main or proximal left anterior descending artery, 34% with total stent 
length ≥ 20mm, and 15%-20% with number of stents, treated arteries, or treated lesions > 1. 
Whether these risks are related to the stent treatment per se or the underlying more 
extensive disease requiring more extensive stent treatment remains unresolved. More 
extensive or severe disease may also be associated with important comorbidities that can 
adversely affect the post-operative risk of myocardial infarction and death. We adjusted 
results for age and gender but did not adjust for other potential confounding comorbidities 
in consideration of the low number of events.  
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The observed higher post-operative risk with coronary stent treatment for 
more extensive or severe disease, although without statistically significant associations, is in 
agreement with previous, smaller, studies in patients treated with bare metal stents.3,4 In 
some larger studies, with higher event rates after surgery, factors such as incomplete 
revascularisation, ostial lesions, distal lesions, and calcified lesions were associated with 
adverse cardiac events after surgery.16,17 
The investigated stent procedure characteristics are not independent, i.e. 
patients treated in more than one artery are treated for more than one lesion and are more 
likely to be treated with more than one stent and longer total stent length. Also, patients 
treated for lesions in the proximal segments of the left coronary artery (segments 5,6,7) are 
more likely to be treated with larger balloon diameters than patients treated for more distal 
lesions.  
As the current study was registry based, we did not have individual level 
information on antiplatelet therapy in relation to surgery. This is a limitation since the 
perioperative handling of antiplatelet therapy in relation to surgery has impact on ischemic 
events.18 It is also a limitation that we were not able to include data on stroke, repeat 
revasularisation or bleeding after surgery. Since we used the Danish National Patient 
Registry for event detection, we were unable to account for stent thrombosis specifically; 
however, any stent thromboses should be detected as either myocardial infarction or death. 
The guidelines generally recommend a careful individual risk assessment 
before undertaking surgery in patients on dual antiplatelet therapy because of recent drug-
eluting stent implantation.1,2  With the current evidence, it remains uncertain how stent 
implantation procedure characteristics should be weighed in this risk assessment. It may be 
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reasonable, in general terms, to consider more extensive coronary drug-eluting stent 
treatment as a risk factor.  
The main limitations of the study are, thus, the missing information on the 
processes for selection of patients for surgery and handling of antiplatelet therapy in 
relation to surgery. The lack of information on the processes for selection of patients for 
surgery is shared with the other studies in this field. The relatively low number of events 
limited the statistical power of the study. 
In conclusion, we identified no significant associations between stent 
implantation procedure characteristics and risk of myocardial infarction or all-cause death 
among patients undergoing non-cardiac surgery within 1-12 months after coronary drug-
eluting stent implantation. All-cause death was lower with first versus second generation 
drug-eluting stents. 
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Figure 1. Study flow chart 
 
 
Figure 2: Kaplan-Meier failure estimate for myocardial infarction (A) and for all-cause death 
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Table 1. Baseline patient characteristics 
 All patients  Myocardial infarction  All-cause death  
 (n=4,046)  Yes (n = 18) No (n = 4,028)  Yes (n = 88) No (n = 3,958) 
Age, years 68 (61-76)  70 (62-81) 68 (61-76)  76 (69-83) 68 (60-75) 
Male gender 2,860 (71%)  12 (67%) 2,848 (71%)  52 (59%) 2,808 (71%) 
Current smoker 1,029 (25%)  4 (22%) 1,025 (25%)  17 (19%) 1,012 (26%) 
Hypercholesterolemia 2,189 (54%)  12 (67%) 2,177 (54%)  44 (50%) 2,145 (54%) 
Hypertension 2,027 (50%)  11 (61%) 2,016 (50%)  48 (55%) 1,979 (50%) 
Diabetes 641 (16%)  2 (11%) 639 (16%)  15 (17%) 626 (16%) 
Previous myocardial infarction 751 (19%)  6 (33%) 745 (18%)  19 (22%) 732 (18%) 
Previous percutaneous coronary 
intervention 
614 (15%)  5 (28%) 609 (15%)  17 (19%) 597 (15%) 
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Table 2. Coronary stent implantation procedure characteristics 
 All patients  Myocardial infarction  All-cause death 
 (n=4,046)  Yes (n = 18) No (n = 4,028)  Yes (n = 88) No (n = 3,958) 
Number of arteries treated (> 1) 792 (20%)  4 (22%) 788 (20%)  16 (18%) 776 (20%) 
Number of lesions treated (> 1) 1,230 (30%)  6 (33%) 1,224 (30%)  27 (31%) 1,203 (30%) 
Treated segments (5, 6, 7*) 1,906 (47%)  11 (61%) 1,895 (47%)  44 (50%) 1,862 (47%) 
Total stent length (≥ 20mm) 2,188 (54%)  11 (61%) 2,177 (54%)  50 (57%) 2,138 (54%) 
Number of stents (> 1) 1,611 (40%)  8 (44%) 1,603 (40%)  37 (42%) 1,574 (40%) 
Stent generation (first 
generation) 
2,488 (61%)  9 (50%) 2,479 (62%)  42 (48%) 2,446 (62%) 
Largest balloon diameter (< 3 
mm) 
997 (25%)  4 (22%) 993 (25%)  26 (30%) 971 (25%) 
* Segment 5: left main stem. Segments 6-7: proximal left anterior descending coronary artery. 
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Table 3. Odd ratios for myocardial infarction and all-cause death within 30 days after non-cardiac surgery according to stent implantation 
procedure characteristics 
 Myocardial infarction  All-cause death 
 Crude OR Adjusted OR  Crude OR Adjusted OR 
Number of arteries treated (> 1) 1.17 (0.39-3.58) 1.15 (0.38-3.52)  0.91 (0.53-1.58) 0.83 (0.48-1.43) 
Number of lesions treated (> 1) 1.15 (0.43-3.06) 1.13 (0.42-3.02)  1.01 (0.64-1.60) 0.94 (0.59-1.49) 
Treated segments (5, 6, 7*) 1.77 (0.68-4.57) 1.77 (0.68-4.57)  1.13 (0.74-1.72) 1.10 (0.72-1.68) 
Total stent length (≥ 20mm) 1.34 (0.52-3.45) 1.34 (0.52-3.48)  1.12 (0.73-1.72) 1.13 (0.74-1.74) 
Number of stents (> 1) 1.21 (0.48-3.07) 1.20 (0.47-3.05)  1.10 (0.72-1.69) 1.06 (0.69-1.62) 
Stent generation (first 
generation) 
0.62 (0.25-1.58) 0.63 (0.25-1.59)  0.56 (0.37-0.86) 0.58 (0.38-0.89) 
Largest balloon diameter (< 3 
mm) 
0.87 (0.29-2.66) 0.86 (0.28-2.61)  1.29 (0.81-2.05) 1.20 (0.76-1.92) 
OR=odds ratio, presented as OR (95% confidence interval). Adjusted for age (≤ or >70 years) and gender. 
* Segment 5: left main stem. Segments 6-7: proximal left anterior descending coronary artery. 
